Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valemetostat tosylate in combination with DXd ADCs for advanced solid tumors
jRCT2031230614Phase 1Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of valemetostat, trastuzumab deruxtecan and datopotamab deruxtecan in Nonhematologic neoplasms, breast cancer, gastric adenocarcinoma and 2 more (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Incidence of dose-limiting toxicities, Incidence of treatment-emergent adverse events and 1 more. Started Apr 2024; status: active, not recruiting.
02
Drugs
valemetostattrastuzumab deruxtecandatopotamab deruxtecan
03
Conditions
Nonhematologic neoplasmsbreast cancergastric adenocarcinomagastroesophageal junction adenocarcinomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031230614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230614.